logo
Twitter
Discord
Email
logo
Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc.

NASDAQ•FOLD
CEO: Mr. Bradley L. Campbell M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2007-05-31
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Contact Information
47 Hulfish Street, Princeton, NJ, 08542, United States
609-662-2000
amicusrx.com
Market Cap
$3.39B
P/E (TTM)
170.7
40.6
Dividend Yield
--
52W High
$11.14
52W Low
$5.51
52W Range
98%
Rank65Top 87.9%
2.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$169.06M+19.46%
4-Quarter Trend

EPS

$0.06-353.85%
4-Quarter Trend

FCF

$35.28M-251.23%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Month Sales Growth Net product sales reached $449.0M for nine months ended September 30, 2025, marking a $70.4M increase.
Q3 Profitability Reversal Q3 2025 generated net income of $17.3M, a significant swing from the $6.7M net loss reported in Q3 2024.
Galafold Commercial Success Galafold revenue for nine months totaled $371.5M, reflecting strong commercial momentum and geographic expansion efforts.

Risk Factors

R&D Expense Spike Nine month R&D costs rose $32.9M to $112.1M, driven by the $30.0M upfront license payment for DMX-200.
Galafold Patent Litigation Litigation with Aurobindo concluded; court decision pending on disputed patent issues affecting Galafold market exclusivity.
Reliance on Pipeline Success Future results heavily depend on clinical trial progress, regulatory approvals for pipeline candidates, and commercialization success.

Outlook

New FSGS Asset Licensed Licensed DMX-200 for FSGS in the U.S. via $30M upfront payment; development milestones total $115M maximum.
Cash Runway Secured Current cash position of $263.8M is deemed sufficient to fund operations and ongoing research for at least 12 months.
ATM Program Availability $164.2M worth of common stock remains available for issuance under the At-The-Market equity program.

Peer Comparison

Revenue (TTM)

Amicus Therapeutics, Inc.FOLD
$598.70M
+21.3%
Catalyst Pharmaceuticals, Inc.CPRX
$578.20M
+25.6%
Arcutis Biotherapeutics, Inc.ARQT
$317.93M
+129.2%

Gross Margin (Latest Quarter)

ImmunityBio, Inc.IBRX
99.4%
-0.6pp
Arcutis Biotherapeutics, Inc.ARQT
91.2%
+3.5pp
Amicus Therapeutics, Inc.FOLD
88.5%
-2.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
BLTE$5.38B-101.8-34.9%0.0%
ARQT$3.47B-81.6-29.7%1.7%
FOLD$3.39B170.79.7%51.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
4.1%
Moderate Growth
4Q Net Income CAGR
5.5%
Profitability Improving
Cash Flow Stability
50%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 18, 2026
|
EPS:$0.14
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 4, 2025|
    Revenue: $169.06M+19.5%
    |
    EPS: $0.06-353.8%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 31, 2025|
    Revenue: $154.69M+22.1%
    |
    EPS: $-0.08+54.7%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 1, 2025|
    Revenue: $125.25M+13.4%
    |
    EPS: $-0.07-55.9%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 19, 2025|
    Revenue: $528.30M+32.3%
    |
    EPS: $-0.18+64.7%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $141.52M+36.7%
    |
    EPS: $-0.02-69.7%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $126.67M+34.0%
    |
    EPS: $-0.05-65.5%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 9, 2024|
    Revenue: $110.40M+28.0%
    |
    EPS: $-0.16-11.1%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 28, 2024|
    Revenue: $399.36M+21.3%
    |
    EPS: $-0.51+37.8%
    Miss